Ποια είναι η τιμή για Arovella Therapeutics Limited (ALA)

Η τιμή για Arovella Therapeutics Limited (ALA) είναι $0.04584351

Ποια είναι η κεφαλαιοποίηση αγοράς για Arovella Therapeutics Limited (ALA)

Η κεφαλαιοποίηση αγοράς για Arovella Therapeutics Limited (ALA) είναι $55.42M

Arovella Therapeutics Limited (ALA) Διαίρεση Μετοχών

Arovella Therapeutics Limited, an Australian biotechnology firm, is dedicated to developing therapeutic solutions for oncology and central nervous system afflictions, operating both domestically and internationally. Its pipeline features several key assets, including ZolpiMist, an oral spray formulation of zolpidem tartrate for the treatment of short-term insomnia, commercially known by brands such as Ambien or Stilnox. The company is also advancing an invariant natural killer T (iNKT) cell therapy platform specifically designed to target blood cancers. Furthermore, Arovella employs OroMist, an oro-mucosal technology enabling the delivery of various drug classes through absorption in the oral cavity via the cheeks, gums, tongue, or mouth floor, and is developing Anagrelide for cancer treatment. Beyond these, the company is engaged in creating oral sprays to address conditions like migraine headaches, motion sickness, and drug-resistant epilepsy. Arovella maintains a research collaboration agreement with Imperial College London. Established in 1999 and based in Osborne Park, Australia, the company was formerly known as Suda Pharmaceuticals Ltd before rebranding to Arovella Therapeutics Limited in October 2021.